<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="81">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 13, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01577069</url>
  </required_header>
  <id_info>
    <org_study_id>UDPS-100211</org_study_id>
    <nct_id>NCT01577069</nct_id>
  </id_info>
  <brief_title>Predictive Factors of the Treatment Failure in Hepatitis C Virus (HCV) Infected Patients Treated With Telaprevir</brief_title>
  <acronym>GENUPI</acronym>
  <official_title>Predictive Factors of the Treatment Failure in HCV Mono-infected Patients Treated With Pegylated-interferon/Ribavirin/Telaprevir.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Association HGE CHU Bordeaux Sud</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Association HGE CHU Bordeaux Sud</source>
  <oversight_info>
    <authority>France: Committee for the Protection of Personnes</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to

      1- detect and quantify HCV-PI resistant mutants with ultra-deep pyrosequencing (UDPS)
      technology, 2 - detect SNPs in P-glyocoprotein and CYP3A genes, in HCV mono-infected
      patients under/after Telaprevir treatment.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2011</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>virological resitance</measure>
    <time_frame>12 weeks after treatment</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">73</enrollment>
  <condition>Chronic Hepatitis C</condition>
  <eligibility>
    <study_pop>
      <textblock>
        HCV mono-infected patients treated in the Hepatology Unit of Pr Victor de Lédinghen
        (Hôpital du Haut-Lévêque, Pessac)
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HCV mono-infected subjects

          -  Age &gt; 18 years

        Exclusion Criteria:

          -  HBV co-infection
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Victor de lédinghen, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Bordeaux</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hôpital du haut-Lévêque</name>
      <address>
        <city>Pessac</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2015</verification_date>
  <lastchanged_date>July 29, 2015</lastchanged_date>
  <firstreceived_date>April 12, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatitis C</keyword>
  <keyword>Direct Antiviral agent (DAA)</keyword>
  <keyword>Ultra-deep pyrosequencing</keyword>
  <keyword>Single polynucleotide polymorphisms</keyword>
  <keyword>Treatment-resistant mutants</keyword>
  <keyword>Hepatitis C Virus Protease Inhibitor</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
